Detalles de la búsqueda
1.
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Cancer
; 130(11): 1940-1951, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38288862
Resultados
1 -
1
de 1
1
Próxima >
>>